UK urothelial carcinoma market is estimated to grow considerably at a CAGR of around 9.4% during the forecast period. UK has one of the finest healthcare systems in the EU region which enables it to provide quality healthcare to the individual citizens. Urothelial carcinoma is by far the most common form of bladder cancer in UK, accounting for over 90% of all new bladder cancers diagnosed, as per Action Bladder Cancer UK (ABC UK). Moreover, about 75-80% of patients that are newly diagnosed with bladder cancer have non-muscle invasive tumors. Numerous factors are affecting the prevalence of the urothelial carcinoma in the country including the increasing population and exposure to a specific type of chemicals among numerous others. Furthermore, the prevalence of urothelial carcinoma is more in men as compared to women in the country, owing to the history of men working in manufacturing plants, thereby exposing themselves to hazardous chemicals which are one of the main causes of the increase in the prevalence of the disease in the country.
To learn more about this report request a sample copy @ https://www.omrglobal.com/industry-reports/uk-urothelial-carcinoma-market
UK urothelial carcinoma market is segmented into diagnosis and treatment. Based on the diagnosis, the market is segmented into cystoscopy, biopsy, urinalysis, urine cytology, intravenous pyelogram (IVP), and others. Based on treatment, the market is segmented into chemotherapy, immunotherapy, radiation therapy, surgery, and other treatment which include targeted therapy. The treatment of the tumor with a monoclonal antibody is considered to be more specific as compared to the chemotherapy drugs, due to their precision. Therefore, immunotherapy is gaining huge traction in the treatment of urothelial carcinoma across the globe.
The companies which are contributing to the growth of the UK urothelial carcinoma market include AstraZeneca PLC, Bristol-Myers Squibb, Co., Eli Lilly & Co., GlaxoSmithKline PLC, Pfizer, Inc. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups, and technological advancements to stay competitive in the market.
UK Urothelial Carcinoma Market- Segmentation
By Diagnosis
- Cystoscopy
- Biopsy
- Urinalysis
- Urine Cytology
- Intravenous Pyelogram (IVP)
- Others (Biomarkers)
By Treatment
- Surgery
- Chemotherapy
- Immunotherapy
- Radiation Therapy
- Others (Targeted Therapy)
A full report of UK Urothelial Carcinoma Market is available at: https://www.omrglobal.com/industry-reports/uk-urothelial-carcinoma-market
Company Profiles
- Astellas Pharma Inc.
- AstraZeneca PLC
- Bayer AG
- Bristol-Myers Squibb Co.
- Eli Lilly and Co.
- Hoffmann-La Roche Ltd.
- GlaxoSmithKline Plc
- Johnson & Johnson Services, Inc.
- Pfizer Inc.
Reasons to Buying From us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research
